Sign in
TerminatedPhase 4

Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study

Key facts

Who runs it
Murdoch Childrens Research Institute
Where
Australia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
13 people enrolled
Started
16 Oct 2017
Ended
30 Jan 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Stoss vitamin D
  • Daily vitamin D
  • Stoss placebo
  • Daily placebo
Record updated
14 March 2025
Why it stopped
Recruitment very slow \& ongoing funding not obtained.

Who can take part

Age
1 year to 12 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • moderate to severe atopic dermatitis with a SCORAD ≥ 20 at baseline
  • aged between 1 ≤ 12 years of age at the time of randomisation
  • regularly ingest the recommended dietary intake (RDI) of calcium and plan to do so for the next 3 months
  • have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf

Who cannot take part

  • use of vitamin D supplementation, including a stoss dose of vitamin D in the previous year, or daily supplementation in the past month
  • received oral steroids within the past 6 months
  • received oral immunosuppression in the past (cyclosporine, azathioprine, methotrexate)
  • received UV therapy in the past 12 months
  • receiving thiazide-type diuretics or anticonvulsant therapy
  • ave renal or liver or gastrointestinal (e.g.: coeliac, inflammatory bowel disease) disease
  • have ever been diagnosed with Hypercalcaemia, Hypertension or Rickets
  • drink vitamin D fortified formula (all formulas) as the main milk intake
  • have been fully formula fed within the past 6 months
  • unable to provide consent without the aid of an interpreter
  • in the opinion of the Investigator, are unable to follow the protocol

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Vitamin D is known to have a regulatory influence on both the immune system and skin barrier function. Studies in paediatric populations have found an inverse association of vitamin D levels and with both prevalence and severity of atopic dermatitis (AD). Trials of vitamin D as a treatment for AD are limited in number and size. There has never been a placebo-controlled randomised controlled trial of stoss high dose versus daily standard dose for the treatment of AD. Further, no trials have explored the presence of vitamin D pathway genes and response to treatment of AD. This pilot study will be used as a reference to determine outcomes and feasibility for undertaking a larger and more in depth definitive study.

The 3 groups in the trial

  • Stoss vitamin DExisting treatment, for comparison

    Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)

    Treatment: Stoss vitamin D and Daily placebo

  • Daily vitamin DExisting treatment, for comparison

    Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)

    Treatment: Daily vitamin D and Stoss placebo

  • PlaceboPlacebo, for comparison

    Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)

    Treatment: Stoss placebo and Daily placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study
Record updated
14 March 2025